Stocktoria
EXICURE, INC. XCUR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-05-09
EXICURE, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $500,000 | $0 | $28.8M | -$483,000 |
| R&D expense | $3.3M | $0 | $1.4M | $19.8M | $49.0M |
| Operating income | -$4.2M | -$12.2M | -$15.0M | -$1.8M | -$62.5M |
| Interest expense | — | — | $0 | $595,000 | $1.7M |
| Income tax | -$634,000 | $8,000 | $0 | $209,000 | $0 |
| Net income | -$4.9M | -$9.7M | -$16.9M | -$2.6M | -$64.1M |
| EPS (diluted) | $-0.79 | $-4.75 | $-10.55 | $-0.56 | $-21.70 |
| Operating cash flow | -$8.6M | -$2.9M | -$10.4M | -$35.7M | -$34.8M |
| Free cash flow | -$8.6M | -$2.9M | -$10.4M | -$35.7M | -$35.8M |
| Cash & equivalents | — | $12.5M | $816,000 | $8.6M | $34.6M |
| Total assets | $14.0M | $15.1M | $11.6M | $23.3M | $64.9M |
| Total liabilities | $10.1M | $8.3M | $8.5M | $8.4M | $53.6M |
| Shareholders' equity | $3.9M | $6.8M | $3.0M | $14.9M | $11.2M |
Source: SEC EDGAR filings · CIK 0001698530 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.